We aimed at comparing the lipid profile and serum levels of leptin, adiponectin and tumor necrosis factor-α (TNF-α) in rats with/without hyperlipidemia and with/without concomitant diabetes mellitus. Forty male 10-week old Wistar rats were divided into 4 groups. Groups A and C received standard food for 12 weeks.
INTRODUCTION
High-density lipoprotein cholesterol (HDL-C) was isolated by precipitating chylomicrons, very low-density lipoprotein cholesterol (VLDL-C) and low-density lipoprotein cholesterol (LDL-C) by adding phosphotungstic acid and magnesium ions to the samples. Serum cholesterol and HDL-C were determined enzymatically by the cholesterol oxidase peroxidase-amidopyrine (CHOD-PAP) method using a commercially available kit (Biosis, Hellas). Serum triglycerides were measured by the enzymatic glycerol-3-phosphate-oxidase peroxidase-amidopyrine (GPO-PAP) method using a commercially available kit (Biosis, Hellas). LDL-C was estimated by the 
Hormonal Measurement
Serum leptin, adiponectin and TNF-α levels were measured by various commercially available rat enzyme-linked immunosorbent assay (ELISA) kits.
Specifically, for leptin levels measurements the R&D Systems ELISA kit was used (catalogue number MOB00), for serum adiponectin levels the ALPCO ELISA kit (catalogue number 44-ADPRT-E01) and for TNF-α levels the INVITROGEN ELISA kit (catalogue number KRC3014). Fasting serum insulin levels were measured by the MERCODIA ELISA kit (catalogue number 10-1124-01).
Statistical Analyses
Data are expressed as mean ± standard deviation for continuous variables and as percentages for categorical data. The Shapiro-Wilk test was used to assess whether the distribution of variables followed the normal distribution. Comparisons of continuous variables were analyzed using the Mann-Whitney nonparametric test as appropriate, while categorical variables were assessed using Spearman's chi-square test. Linear relationships between quantitative variables were assessed with to analyze the effects of each measured variable, not only within the groups but also between different groups (primary assumption: covariates such as age, sex, weight are already normalized, due to the fact that the rats used in the experiment are set as equal from the start). All statistical tests were examined in a 5% level of significance. In other words, null hypothesis is rejected with >95% confidence (confidence interval 2 tailed P < 0.5).
RESULTS

Determination of Diabetes
Animals injected with streptozotocin became markedly diabetic as manifested by fasting serum glucose levels (Tables 1, 2) . Baseline values of glucose were similar in all groups. Two rats in group D died on days 2 and 3, respectively, after streptozotocin injection. The diabetic animals presented with increased polyuria, polyphagia and polydipsia compared with the control group. Fasting serum glucose levels were significantly higher in groups C and D compared with the control groups (Tables 2, 3) (A: 153.00 ± 14.4 mg/dL; B: 114.00 ± 35.7 mg/dL; C: 255.30 ± 129.9 mg/dL; D: 244.50 ± 209.9 mg/dL; P < 0.01). There was no significant difference in insulin and HOMA-R levels among the groups.
Lipid Profile
Total cholesterol in group D was increased compared with the control group (Tables 3, 4) . LDL-C levels were increased in group D compared with controls (A: 22.65 ± 12.8 mg/dL; C: 14.63 ± 9.4 mg/dL; D: 105.90 ± 143.6 mg/dL; P < 0.05). LDL-C levels also varied among the diabetic groups (C vs D; P < 0.05).
HDL-C levels were decreased in group B compared with controls (Tables 2, 3), while there was no significant difference among the diabetic group (Table 4) .07 ng/mL; P < 0.01). Adiponectin levels were also decreased in group B compared with group A (P < 0.001) ( Table 3) . No difference in adiponectin levels was found among groups C and D (Table 4) . Leptin levels were correlated to fasting insulin (r = 0.420, P < 0.05) and glucose (r = -0.415, P < 0.05).
Adiponectin was correlated to glucose (r = -0.359, P < 0.05) and leptin (r = 0.530, P < 0.01).
Serum TNF-α levels were increased in groups B and D fed with atherogenic diet compared with group A (Tables 2, 3) (A: 2.02 ± 0.7 pg/mL; B: 20.51 ± 18.4 pg/mL; D: 10.52 ± 19.7 pg/mL; P < 0.05). In contrast, TNF-α levels were decreased in group C compared with group B and D (P < 0.005) ( Table 4 ). TNF-α was Molecular Medicine www.molmed.org UNCORRECTED PROOF correlated to total cholesterol (r = 0.754, P < 0.005) and HDL-C (r = 0.823, P < 0.001).
DISCUSSION
Our study demonstrates that serum leptin, adiponectin and TNF-α levels were altered after the induction of DM I and/or hyperlipidemia. 
UNCORRECTED PROOF
are decreased in DM II (6,20,21). By contrast, adiponectin levels are increased in patients with DM I (32). An immune mechanism has been proposed to account for this increase (32). We found decreased adiponectin levels in hyperlipidemic rats alone, in DM I animals alone, as well as in those ones having both DM I and hyperlipidemia. The reason may be the lack of an immune mechanism that leads to β-cell damage and absolute insulin deficiency in our model of streptozotocin-induced diabetes. It was recently suggested that the high-molecular weight form of adiponectin may serve as a significant surrogate marker for the prediction of DM II in the Japanese population (33). An earlier report posed that decreased total and highmolecular weight adiponectin levels are independent risk factors for the development of DM II in Japanese-Americans (34). Finally, the high-molecular weight multimeric form of adiponectin may serve as a useful marker to evaluate insulin resistance and the metabolic syndrome in men (6,35). Thus, there is already preliminary evidence suggesting that adiponectin may serve as an early marker of DM.
Besides being an early marker of the metabolic syndrome, insulin resistance and DM II (33-35), low plasma adiponectin levels are also a marker of subclinical atherosclerosis. In a study performed 8 years ago, circulating adiponectin levels were demonstrated to correlate with the presence of early atherosclerosis, as measured by an increased intima media thickness in the carotid artery bulb (36). These results were verified a few years later (37). Plasma adiponectin levels were shown to be a marker of glucose metabolism and obesity, as well as carotid intima media thickness in a large study (n = 887) of middle-aged individuals (37). Finally, a recent study confirmed that serum adiponectin levels are associated with indices of subclinical atherosclerosis (such as intima media thickness and arterial compliance) in obese patients (38).
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TNF-α levels are increased both in DM (33,34) as well as in obesity (35). We also found increased TNF-α levels in animals receiving high-fat diet. It is well known and firmly established that TNF-α levels serve as markers of both obesity and cachexia (23,24,39). In the absence of high-fat diet, TNF-α levels were low and similar to the control group despite the induction of DM I. Again, the reason for this variation may be the lack of similarities at the molecular level between DM I and the streptozotocin-induced diabetes in our model. This finding is in contrast with studies performed on humans with DM I more than 10 years ago, which showed that in patients with DM I, TNF-α levels are elevated compared with non-diabetic individuals and correlate with the quality of glycaemic control (40,41).
In our study, although animals fed with high-fat diet presented hypercholesterolemia, no difference was observed in leptin and adiponectin levels among diabetic groups with different lipid profile. This finding is in agreement with the weak correlation between these hormones and levels of total cholesterol. In contrast, TNF-α levels had significant difference between diabetic groups with different lipid profile. The reason may be the strong correlation between total cholesterol and TNF-α levels. This acute increase of TNF-α levels in subclinical dyslipidemia suggests that TNF-α levels are useful indicators of inflammation and a tool to optimize therapeutic management and reduce diabetic complications. 
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